Coal Tar, Filaggrin and Eczema: What a Laboratory Mechanism Can—and Cannot—Prove
“Supports the skin barrier” can describe very different kinds of evidence. A laboratory finding about a receptor or protein is useful for understanding biology, but it is not the same as showing how much a person's eczema improves. Coal-tar research offers a clear example of why those levels of evidence need to stay separate.
What the 2013 study investigated
A 2013 study in the Journal of Clinical Investigation examined cultured human skin cells and reconstructed skin models. Researchers explored whether coal tar acted through the aryl hydrocarbon receptor, or AHR. When they reduced AHR using a laboratory gene-silencing technique, the observed differentiation response was abolished. This supported a causal role for that receptor in the experimental system.
The researchers also studied skin equivalents from three donors with a single faulty FLG copy and three wild-type donors, and examined biopsies from three people receiving coal-tar therapy. Filaggrin and other barrier-protein staining increased during treatment. These small experimental and biopsy components were not a large randomized trial measuring symptoms, quality of life or long-term safety.
Restoring protein expression is not editing a gene
Our filaggrin and genetics guide explains the distinction between a gene and the proteins made through its activity. Finding more protein in a model does not show that a person's inherited DNA was corrected. It also does not demonstrate that every cause of eczema has been removed.
A before-and-during biopsy comparison can show biological changes, but it does not isolate all the influences on a patient's clinical course. A receptor experiment can investigate mechanism while leaving separate questions about benefit, dose, tolerability and practical use unanswered. Those are complementary research questions, not interchangeable endpoints.
| Research observation | What it cannot establish alone |
|---|---|
| AHR silencing removes a response | How well a finished treatment works in everyday clinical care. |
| More filaggrin staining | Gene correction or permanent eczema remission. |
| Three-patient biopsy component | A population response rate or long-term safety estimate. |
| Two treatments involve the same target | Equal efficacy, equal exposure or equal safety. |
Do not borrow evidence across products
Our tapinarof ADORING trial guide discusses a separately studied medicine. A shared interest in AHR biology does not make a prescription cream, coal-tar preparation and cosmetic moisturizer equivalent. The active substances, concentrations, formulation and clinical evidence all matter.
The same rule applies to ingredient marketing. A mechanism reported for one substance cannot be transferred to another finished product simply because both are described as supporting a barrier. The coal-tar research did not test Dr. Arsy #003 and cannot substantiate an eczema-treatment claim for it.
Turn the science into useful appointment questions
If coal tar is proposed, ask about the exact medical preparation, the reason for choosing it, alternatives, directions and how response and unwanted effects will be reviewed. Do not use industrial tar, formulate a homemade preparation or copy a laboratory exposure concentration onto skin. This paper is not a consumer dosing guide.
The NIAMS treatment overview places skin care within an individualized plan. For a child or someone with other medical needs, suitability needs a separate clinical assessment. A useful question is not merely whether a treatment changes a molecule, but whether the proposed plan has evidence for the outcomes and safety concerns that matter to that person.
Ask which kind of evidence supports the promise
When a claim concerns symptom improvement, look for appropriate clinical comparisons as well as mechanism. Our montelukast review illustrates limits even when a pooled adult subgroup is favorable. The homeopathy evidence discussion addresses a different intervention and shows why a result on one outcome is not proof of every benefit. Neither example can validate coal tar or a cosmetic by analogy.
Sources and reading notes
Prepared by the Dr. Arsy Editorial Team. Sources checked November 8, 2026. Educational information; no independent clinician review is implied. PubMed indexing is not NIH endorsement. Researchers and organizations cited do not endorse #003. The image is an AI-created editorial scene based on the actual jar, not a patient photo or study result.